Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by TeddyTenBagson Feb 11, 2021 10:01pm
234 Views
Post# 32548882

RE:How do psychedelic companies make money?

RE:How do psychedelic companies make money?

Number 1 is really the only blockbuster moneymaker in the space, but you're thinking about it all wrong, especially by comparing to marijuana.

The big play here is pharmaceutical. Whereas the big play for weed was recreational. For the most part, at least to start in the next 5+ years, these drugs will predominantly be used in a clinical setting. Many of these drugs/therapies will be covered by health insurance and benefits, where there would be no need for someone to go buy unsafe products from the grey/black market. Where would you rather buy/take these drugs? Clinical setting/covered by insurance? Or off the street and take the risk?

If you're thinking there will be Recreational psychedelics - those are a longggggg way off, which is the big difference between this and weed. 


Jiminee wrote: I see three types of activities and some companies will have all three.


1) growing, producing, manufacturing drugs
2) psychotherapy services accompanying use of drugs
3) associated services, eg media, patient management, etc.

(1) I know drugs are being patented, but how different will these drugs --- even if they are synthesized -- be from what can be bought on the grey market, as now occurs for marijuana which underprices the legal product?

(2) I wonder how profitable these services can be. Also, stand alone psychotherapists, with much lower overheads, could compete directly with these companies.

(3) What kind of companies here will be profitable?

Thankyou for your assistance.


 

<< Previous
Bullboard Posts
Next >>